Compare Core Scientific Inc (CORZ) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Incyte Corporation — how do they compare? Core Scientific Inc trades at $15.28 (market cap $4.94B), while Incyte Corporation trades at $113.51 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 4.6× Core Scientific Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Incyte Corporation for 33 Days on average.
| CORZ | INCY | |
|---|---|---|
Market Cap | $4.94B | $22.85B |
Volume | 15,630,800 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $29.16 | $129.93 |
52-Week Low | $13.57 | $83.80 |
Typical Hold Time | 20 Days | 33 Days |
Enterprise Value | $7.46B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CORZ trades at $15.25, down 4.36% today amid a bearish technical trend. The stock shows weak fundamentals with a net loss of $288.62 million in 2025 and negative profit margins, though revenue is projected to grow to $440 million in 2026. Analyst sentiment remains strongly bullish with an 86% buy rating and a $32.75 consensus price target, but recent earnings misses and high cash burn pose significant risks.
The outlook is mixed: strong analyst support and insider buying suggest confidence in the AI data center strategy, but persistent losses, negative cash flow, and competitive pressures require careful monitoring. The stock's current price near support levels offers potential upside if execution improves, yet volatility and operational challenges present substantial downside risk.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
